FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands
Executive Summary
Pfizer, AbbVie and Lilly will face new safety restrictions on Xeljanz, Rinvoq and Olumiant. Indication expansion remains uncertain, while first-line use appears out of the question.
You may also be interested in...
AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.
Pfizer Highlights Next I&I Star As Xeljanz Sales Fall
The company is looking to refuel its immunology & inflammation portfolio as Xeljanz safety takes a toll and the franchise approaches loss of exclusivity.
AOBiome Targets Atopic Dermatitis Niche With Bacteria-Based Drug
While the atopic dermatitis market overall is crowded, the company sees a market opportunity for a drug that addresses both appearance and itching, as well as having favorable safety and ease of use.